Business
Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo's Canadian Portfolio
MONTREAL and MARLBOROUGH, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:...
About this update from Knight Therapeutics, Inc.
[{"type":"text","content":"Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo’s Canadian Portfolio\n\n\n\n MONTREAL and MARLBOROUGH, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (\"Knight\"), a pan-American (ex-USA) specialty pharmaceutical company, and Sumitomo Pharma America Inc. (“SMPA”) announced today that Knight and SMPA’s affiliates have entered into exclusive license and supply agreements to commercialize MYFEMBREE\n \n ®\n \n (relugolix/estradiol/norethindrone acetate), ORGOVYX\n \n ®\n \n (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight will acquire certain mature products (the “Mature Products”, together with MYFEMBREE\n \n ®\n \n , ORGOVYX\n \n ®\n \n and vibegron, the “Products”). For the year ended March 2025, the Products generated C$11.2 million in revenue.\n \n\n Under the terms of the agreements, Knight will have the exclusive rights to distribute, promote, market and sell the Products in Canada. Knight will begin commercial activities following a transition period from Sumitomo Pharma Canada. The consideration for the transaction includes an upfront amount of C$25.4 million and Knight may pay future contingent payments of up to C$15.75 million upon achieving certain sales milestones. In addition, Knight is expected to pay an estimated C$7 million for inventory to be acquired over the next eight months.\n \n\n “We are pleased that Knight will continue to bring this suite of products to patients and health care providers throughout Canada,” said Tsutomu Nakagawa, Ph.D., President and Chief Executive Officer of SMPA. “This divestiture is aligned with our long-term strategy to focus on and grow our core brands in the U.S. and to accelerate commercialization of our pipeline assets for oncology, regenerative medicine and cell therapy.”\n \n\n “This transaction is another great example of our continued execution on our growth strategy of building a portfolio of innovative products,” said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics Inc. “MYFEMBREE\n \n ®\n \n , ORGOVYX\n \n ®\n \n and vibegron are highly synergistic with our current Canadian bu...